<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157455</url>
  </required_header>
  <id_info>
    <org_study_id>SEEDS</org_study_id>
    <nct_id>NCT01157455</nct_id>
  </id_info>
  <brief_title>A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization</brief_title>
  <acronym>SEEDS</acronym>
  <official_title>Clinical Trial Program of a Medical Instrument Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCRF Consulting Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CCRF Consulting Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center registry to evaluate safety and effectiveness of the&#xD;
      Everolimus Drug Eluting Stent for treatment coronary revascularization in Chinese patients&#xD;
      with long lesion, small vessel or multi-vessel diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Device:The XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V EECSS or XIENCE&#xD;
      V stent system) is a device/drug combination product consisting of either the MULTI-LINK&#xD;
      VISION® Coronary Stent System or the MULTI-LINK MINI VISION® Coronary Stent System coated&#xD;
      with a formulation containing everolimus, the active ingredient, embedded in a non-erodible&#xD;
      polymer. Design:A prospective, multi-center, registry that is designed to enroll Chinese&#xD;
      patients with either Long Lesion, or Small Vessel or Multi-Vessel diseases. Purpose:To&#xD;
      evaluate the safety and effectiveness of the XIENCE V® everolimus drug eluting stent for&#xD;
      coronary revascularization of patients with either long lesion, or small vessel, or&#xD;
      multi-vessel diseases. Enrollment:Approximately 1900 patients will be enrolled in at least 45&#xD;
      but up to 51 centers. Mainland China 41 up to 47 centers, Taiwan China 3 centers and Macao&#xD;
      China 1 center. This registry is planned to enroll at least 50% of patients with multi-vessel&#xD;
      disease. Primary Endpoint:Ischemia-driven Target Vessel Failure (TVF) which is a composite of&#xD;
      cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization&#xD;
      (TVR) at 12 months post-index procedure. Follow-Up Visits:30 days, 6 months, 12 months, and&#xD;
      24 months post index procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TVF</measure>
    <time_frame>12 months post-index procedure.</time_frame>
    <description>Ischemia-driven Target Vessel Failure (TVF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization (TVR),12 months post-index procedure.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1900</enrollment>
  <condition>Coronary Artery Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Everolimus Drug Eluting Stent</intervention_name>
    <description>Implantation</description>
    <other_name>XIENCE(TM) V EECSS</other_name>
    <other_name>XIENCE(TM) V stent system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.&#xD;
75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin or Bivalirudin</intervention_name>
    <description>During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥18 of age; male or (non-pregnant and non-breast feeding) female.&#xD;
&#xD;
          2. Diagnosis of stable angina, unstable angina or silent ischemia (evidence of myocardial&#xD;
             ischemia).&#xD;
&#xD;
          3. Target lesion is at least length ≥ 25mm (visual estimate); or the number of target&#xD;
             lesion is ≥ 2; or target vessel diameter ≤ 2.75mm.&#xD;
&#xD;
          4. At least one target lesion with a diameter stenosis ≥70% (visual estimate)&#xD;
&#xD;
          5. Acceptable candidate for CABG;&#xD;
&#xD;
          6. The patient or legally authorized representative has been informed of the nature of&#xD;
             the study, agrees to its provisions and has been provided written Notice of Informed&#xD;
             Consent, appropriate Ethics Committee(EC); and the patient is willing to comply with&#xD;
             specified follow-up evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have evidence of an Acute Myocardial Infarction within a week prior to the&#xD;
             index procedure.&#xD;
&#xD;
          2. Patient has congenital heart disease, severe valve dysfunction, bridge vascular&#xD;
             disease, severe heart failure (NYHA ≥ Ⅲ level), or left ventricular ejection fraction&#xD;
             ≤ 30%.&#xD;
&#xD;
          3. Patient has undergone previous stenting anywhere within the previous 1 year.&#xD;
&#xD;
          4. Patient has a preoperative renal dysfunction: serum creatinine&gt; 2.0mg/dl (176.82umol /&#xD;
             L).&#xD;
&#xD;
          5. Patient has a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             anti-platelet and/or anticoagulant therapy is contraindicated or in which patient will&#xD;
             not be able to comply with dual antiplatelet therapy for at least 1 year;&#xD;
&#xD;
          6. Patient has a known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, clopidogrel/ticlopidine, Prasugrel, stainless steel alloy, cobalt&#xD;
             chromium, rapamycin, styrene-butylene-styrene or poly-lactic acid (PLA) polymer,&#xD;
             and/or contrast sensitivity that cannot be adequately premedicated; Patient is&#xD;
             allergic to contrast agent Sirolimus.&#xD;
&#xD;
          7. Patient has other medical illness (e.g., cancer, known malignancy , congestive heart&#xD;
             failure, organ transplant recipient or candidate) or known history of substance abuse&#xD;
             (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol,&#xD;
             confound the data interpretation or is associated with a limited life expectancy is&#xD;
             less than 12 months.&#xD;
&#xD;
          8. Currently participating in another investigational drug or device study or patient in&#xD;
             inclusion in another investigational drug or device study during follow-up&#xD;
&#xD;
          9. Any significant medical condition which in the Investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study; Patient has poor compliance&#xD;
             with the judgment of the investigator and can not complete the study as required.&#xD;
&#xD;
         10. Patient who had heart transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuejin Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Liu</last_name>
    <phone>010-84094934</phone>
    <phone_ext>816</phone_ext>
    <email>bliu@ccrfmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuejin Yang</last_name>
      <email>yangyjfw@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Bo Xu</last_name>
      <email>xubofuwai@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>July 5, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bo Liu</name_title>
    <organization>CCRF</organization>
  </responsible_party>
  <keyword>Stent</keyword>
  <keyword>Coronary artery diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

